Cancer Treatment

View All

Immunomodulators Market and Key Applications
Harnessing the Power of Immunomodulators: Applications and Implications

The human immune system has a magnificent defense system that works continuously to protect the body from numerous infections and outside invaders. Maintaining a healthy immune response through the intricate interplay of cells, chemicals, and signaling pathways is essential for general health and well-being. Immuno...

Find More

antibody-drug-conjugates-adcs-in-oncology
Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...

Find More

cancer-diagnostics-market-landscape
Cancer Diagnostic Market: Evaluating the Major Growth Factors and the Key Developments in the Domain

Cancer is a global burden, leading to a significant number of death and disabilities worldwide. In 2020, nearly one in six deaths were related to cancer. Breast cancer, lung cancer, colon and rectum cancer, and prostate cancer are some of the major cancer types, registering the highest number of cases globally. To ...

Find More

immune-oncology-therapeutics-for-cancer-treatment
Immuno-Oncology (I-O) Therapeutics: The Key to Future Cancer Treatment

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...

Find More

cancer-biomarkers-for-cancer-treatment
Cancer Biomarkers: Improving Treatment and Detection

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Find More

minimal-residue-disease-mrd-testing-market
Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?

Measurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...

Find More

top-10-oncology-drugs-launches-2023
Top 10 Expected Oncology Drug Launches in 2023

Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...

Find More

MedTech News and Updates for Vivos, Arthrex, Chindex, Glaukos, Zimmer Biomet
Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

Find More

enhertu-for-cancer-treatment-and-management
ENHERTU’s Journey in Cancer Treatment and Management

ENHERTU is an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this ADC:  A topoisomerase inhibitor that is covalently linked to, Humanized anti-HER2 IgG1 monoclonal antibody (mAb) via, Tetrapeptide-based cleavable linker Rec...

Find More

Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in RR DLBCL
ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

Find More